Cargando…
Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China
BACKGROUND: Anti-tuberculosis drug induced liver injury (ATLI) is emerging as a significant threat to tuberculosis control in China, though limited data is available about the burden of ATLI at population level. This study aimed to estimate the incidence of ATLI, to better understand its clinical fe...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130045/ https://www.ncbi.nlm.nih.gov/pubmed/21750735 http://dx.doi.org/10.1371/journal.pone.0021836 |
_version_ | 1782207578939326464 |
---|---|
author | Shang, Penghui Xia, Yinyin Liu, Feiying Wang, Xiaomeng Yuan, Yanli Hu, Daiyu Tu, Dehua Chen, Yixin Deng, Peiyuan Cheng, Shiming Zhou, Lin Ma, Yu Zhu, Lizhen Gao, Weiwei Wang, Hongyuan Chen, Dafang Yang, Li He, Pingping Wu, Shanshan Tang, Shaowen Lv, Xiaozhen Shu, Zheng Zhang, Yuan Yang, Zhirong Chen, Yan Li, Na Sun, Feng Li, Xiaoting He, Yingjian Garner, Paul Zhan, Siyan |
author_facet | Shang, Penghui Xia, Yinyin Liu, Feiying Wang, Xiaomeng Yuan, Yanli Hu, Daiyu Tu, Dehua Chen, Yixin Deng, Peiyuan Cheng, Shiming Zhou, Lin Ma, Yu Zhu, Lizhen Gao, Weiwei Wang, Hongyuan Chen, Dafang Yang, Li He, Pingping Wu, Shanshan Tang, Shaowen Lv, Xiaozhen Shu, Zheng Zhang, Yuan Yang, Zhirong Chen, Yan Li, Na Sun, Feng Li, Xiaoting He, Yingjian Garner, Paul Zhan, Siyan |
author_sort | Shang, Penghui |
collection | PubMed |
description | BACKGROUND: Anti-tuberculosis drug induced liver injury (ATLI) is emerging as a significant threat to tuberculosis control in China, though limited data is available about the burden of ATLI at population level. This study aimed to estimate the incidence of ATLI, to better understand its clinical features, and to evaluate its impact on anti-tuberculosis (TB) treatment in China. METHODOLOGY/PRINCIPAL FINDINGS: In a population-based prospective study, we monitored 4,304 TB patients receiving directly observed treatment strategy (DOTS) treatment, and found that 106 patients developed ATLI with a cumulative incidence of 2.55% (95% Confidence Interval [CI], 2.04%–3.06%). Nausea, vomiting and anorexia were the top three most frequently observed symptoms. There were 35 (33.02%) ATLI patients with no symptoms, including 8 with severe hepatotoxicity. Regarding the prognosis of ATLI, 84 cases (79.25%) recovered, 18 (16.98%) improved, 2 (1.89%) failed to respond to the treatment with continued elevation of serum alanine aminotransferase, and 2 (1.89%) died as result of ATLI. Of all the ATLI cases, 74 (69.81%) cases changed their anti-TB treatment, including 4 (3.77%) cases with medication administration change, 21 (19.81%) cases with drugs replacement, 54 (50.94%) cases with therapy interruption, and 12 (11.32%) cases who discontinued therapy. In terms of treatment outcomes, 53 (51.46%) cases had TB cured in time, 48 (46.60%) cases had therapy prolonged, and 2 (1.94%) cases died. Compared with non-ATLI patients, ATLI patients had a 9.25-fold (95%CI, 5.69–15.05) risk of unsuccessful anti-TB treatment outcomes and a 2.11-fold (95%CI,1.23–3.60) risk of prolonged intensive treatment phase. CONCLUSIONS/SIGNIFICANCE: ATLI could considerably impact the outcomes of anti-TB treatment. Given the incidence of ATLI and the size of TB population in China, the negative impact is substantial. Therefore, more research and efforts are warranted in order to enhance the diagnosis and the prevention of ATLI. |
format | Online Article Text |
id | pubmed-3130045 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-31300452011-07-12 Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China Shang, Penghui Xia, Yinyin Liu, Feiying Wang, Xiaomeng Yuan, Yanli Hu, Daiyu Tu, Dehua Chen, Yixin Deng, Peiyuan Cheng, Shiming Zhou, Lin Ma, Yu Zhu, Lizhen Gao, Weiwei Wang, Hongyuan Chen, Dafang Yang, Li He, Pingping Wu, Shanshan Tang, Shaowen Lv, Xiaozhen Shu, Zheng Zhang, Yuan Yang, Zhirong Chen, Yan Li, Na Sun, Feng Li, Xiaoting He, Yingjian Garner, Paul Zhan, Siyan PLoS One Research Article BACKGROUND: Anti-tuberculosis drug induced liver injury (ATLI) is emerging as a significant threat to tuberculosis control in China, though limited data is available about the burden of ATLI at population level. This study aimed to estimate the incidence of ATLI, to better understand its clinical features, and to evaluate its impact on anti-tuberculosis (TB) treatment in China. METHODOLOGY/PRINCIPAL FINDINGS: In a population-based prospective study, we monitored 4,304 TB patients receiving directly observed treatment strategy (DOTS) treatment, and found that 106 patients developed ATLI with a cumulative incidence of 2.55% (95% Confidence Interval [CI], 2.04%–3.06%). Nausea, vomiting and anorexia were the top three most frequently observed symptoms. There were 35 (33.02%) ATLI patients with no symptoms, including 8 with severe hepatotoxicity. Regarding the prognosis of ATLI, 84 cases (79.25%) recovered, 18 (16.98%) improved, 2 (1.89%) failed to respond to the treatment with continued elevation of serum alanine aminotransferase, and 2 (1.89%) died as result of ATLI. Of all the ATLI cases, 74 (69.81%) cases changed their anti-TB treatment, including 4 (3.77%) cases with medication administration change, 21 (19.81%) cases with drugs replacement, 54 (50.94%) cases with therapy interruption, and 12 (11.32%) cases who discontinued therapy. In terms of treatment outcomes, 53 (51.46%) cases had TB cured in time, 48 (46.60%) cases had therapy prolonged, and 2 (1.94%) cases died. Compared with non-ATLI patients, ATLI patients had a 9.25-fold (95%CI, 5.69–15.05) risk of unsuccessful anti-TB treatment outcomes and a 2.11-fold (95%CI,1.23–3.60) risk of prolonged intensive treatment phase. CONCLUSIONS/SIGNIFICANCE: ATLI could considerably impact the outcomes of anti-TB treatment. Given the incidence of ATLI and the size of TB population in China, the negative impact is substantial. Therefore, more research and efforts are warranted in order to enhance the diagnosis and the prevention of ATLI. Public Library of Science 2011-07-05 /pmc/articles/PMC3130045/ /pubmed/21750735 http://dx.doi.org/10.1371/journal.pone.0021836 Text en Shang et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Shang, Penghui Xia, Yinyin Liu, Feiying Wang, Xiaomeng Yuan, Yanli Hu, Daiyu Tu, Dehua Chen, Yixin Deng, Peiyuan Cheng, Shiming Zhou, Lin Ma, Yu Zhu, Lizhen Gao, Weiwei Wang, Hongyuan Chen, Dafang Yang, Li He, Pingping Wu, Shanshan Tang, Shaowen Lv, Xiaozhen Shu, Zheng Zhang, Yuan Yang, Zhirong Chen, Yan Li, Na Sun, Feng Li, Xiaoting He, Yingjian Garner, Paul Zhan, Siyan Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China |
title | Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China |
title_full | Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China |
title_fullStr | Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China |
title_full_unstemmed | Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China |
title_short | Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China |
title_sort | incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (atli) in china |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130045/ https://www.ncbi.nlm.nih.gov/pubmed/21750735 http://dx.doi.org/10.1371/journal.pone.0021836 |
work_keys_str_mv | AT shangpenghui incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT xiayinyin incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT liufeiying incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT wangxiaomeng incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT yuanyanli incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT hudaiyu incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT tudehua incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT chenyixin incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT dengpeiyuan incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT chengshiming incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT zhoulin incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT mayu incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT zhulizhen incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT gaoweiwei incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT wanghongyuan incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT chendafang incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT yangli incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT hepingping incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT wushanshan incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT tangshaowen incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT lvxiaozhen incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT shuzheng incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT zhangyuan incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT yangzhirong incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT chenyan incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT lina incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT sunfeng incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT lixiaoting incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT heyingjian incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT garnerpaul incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina AT zhansiyan incidenceclinicalfeaturesandimpactonantituberculosistreatmentofantituberculosisdruginducedliverinjuryatliinchina |